Compass Therapeutics Inc. (CMPX) Stock Analysis
Verdict: AVOID
Tovecimig's PFS benefit is clouded by OS crossover data, creating a binary FDA regulatory outcome with severe dilution risk on rejection.
Investment score: 35/100
Analysis as of
Is Compass Therapeutics Inc. stock worth reviewing? AI model thesis
The model recommends AVOID on CMPX due to high binary regulatory risk surrounding lead asset tovecimig, steep 30-day technical degradation (-44.1%), and zero commercial revenue despite a manageable $179.88M USD cash balance.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 35/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Compass Therapeutics Inc. opportunities and risks
What speaks for CMPX
- Statistically significant PFS benefit in COMPANION-002 trial
What speaks against CMPX
- Overall survival crossover contamination clouds FDA approval path
Frequently asked questions about Compass Therapeutics Inc. (CMPX)
Is CMPX stock a good investment?
The cached TradeMates AI model rates Compass Therapeutics Inc. as AVOID with an investment score of 35/100. The model recommends AVOID on CMPX due to high binary regulatory risk surrounding lead asset tovecimig, steep 30-day technical degradation (-44.1%), and zero commercial revenue despite a manageable $179.88M USD cash balance. This is algorithmic model output, not personal investment advice.
Is CMPX stock a buy?
The TradeMates model verdict for CMPX is AVOID with an investment score of 35/100. Treat this as a model signal to review, not a personal buy recommendation.